Sun Pharmaceutical Industries announced a 20% decline in its consolidated net profit for the first quarter of 2025, reporting Rs 2,279 crore compared to Rs 2,836 crore for the same period last year.
Adjusted net profit, which excludes exceptional items, showed a 6% year-on-year increase to Rs 2,996 crore. Total income also saw an uptrend, rising to Rs 14,316 crore from Rs 13,185 crore the previous year.
According to Chairman and Managing Director Dilip Shanghvi, the Mumbai-based drug major has shown steady growth across its markets, bolstered by strong performance in India and the US launch of LEQSELVI, a new treatment for severe alopecia areata. Despite this optimistic scenario, shares of the company fell by 2.04% on the BSE.
